TXG 10x Genomics Inc

Price (delayed)

$27.94

Market cap

$3.33B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.18

Enterprise value

$3.07B

10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin ...

Highlights
10x Genomics's revenue has increased by 20% YoY and by 4.7% from the previous quarter
The company's gross profit rose by 3.4% YoY
The company's net income has shrunk by 54% YoY and by 14% QoQ
TXG's EPS is down by 49% year-on-year and by 14% since the previous quarter

Key stats

What are the main financial stats of TXG
Market
Shares outstanding
119.17M
Market cap
$3.33B
Enterprise value
$3.07B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.46
Price to sales (P/S)
5.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.95
Earnings
Revenue
$618.73M
EBIT
-$248.73M
EBITDA
-$205.11M
Free cash flow
-$63.8M
Per share
EPS
-$2.18
Free cash flow per share
-$0.54
Book value per share
$6.27
Revenue per share
$5.28
TBVPS
$8.06
Balance sheet
Total assets
$965.14M
Total liabilities
$224.1M
Debt
$95.37M
Equity
$741.04M
Working capital
$468.86M
Liquidity
Debt to equity
0.13
Current ratio
4.69
Quick ratio
3.96
Net debt/EBITDA
1.29
Margins
EBITDA margin
-33.2%
Gross margin
66.2%
Net margin
-41.2%
Operating margin
-42.9%
Efficiency
Return on assets
-26%
Return on equity
-33.1%
Return on invested capital
-41%
Return on capital employed
-29.7%
Return on sales
-40.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TXG stock price

How has the 10x Genomics stock price performed over time
Intraday
-3.49%
1 week
-19.13%
1 month
-25.35%
1 year
-49.2%
YTD
-50.07%
QTD
-25.55%

Financial performance

How have 10x Genomics's revenue and profit performed over time
Revenue
$618.73M
Gross profit
$409.31M
Operating income
-$265.33M
Net income
-$255.1M
Gross margin
66.2%
Net margin
-41.2%
TXG's operating income has dropped by 58% year-on-year and by 14% since the previous quarter
The company's net income has shrunk by 54% YoY and by 14% QoQ
10x Genomics's operating margin has decreased by 32% YoY and by 9% QoQ
10x Genomics's net margin has decreased by 28% YoY and by 9% QoQ

Growth

What is 10x Genomics's growth rate over time

Valuation

What is 10x Genomics stock price valuation
P/E
N/A
P/B
4.46
P/S
5.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.95
TXG's EPS is down by 49% year-on-year and by 14% since the previous quarter
The P/B is 68% below the 5-year quarterly average of 14.1 and 44% below the last 4 quarters average of 7.9
TXG's equity is down by 8% year-on-year
The stock's price to sales (P/S) is 78% less than its 5-year quarterly average of 24.3 and 50% less than its last 4 quarters average of 10.6
10x Genomics's revenue has increased by 20% YoY and by 4.7% from the previous quarter

Efficiency

How efficient is 10x Genomics business performance
The return on invested capital has dropped by 76% year-on-year and by 22% since the previous quarter
TXG's ROA has plunged by 58% YoY and by 16% from the previous quarter
The ROE has plunged by 58% YoY and by 17% from the previous quarter
TXG's ROS is down by 28% year-on-year and by 9% since the previous quarter

Dividends

What is TXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TXG.

Financial health

How did 10x Genomics financials performed over time
The current ratio has contracted by 13% from the previous quarter and by 3.3% YoY
The company's quick ratio fell by 11% QoQ and by 4.3% YoY
10x Genomics's debt is 87% lower than its equity
10x Genomics's debt to equity has increased by 8% YoY
TXG's equity is down by 8% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.